Sinclair S B, Greig P D, Blendis L M, Abecassis M, Roberts E A, Phillips M J, Cameron R, Levy G A
Liver Disease Program, University of Toronto, Ontario, Canada.
J Clin Invest. 1989 Oct;84(4):1063-9. doi: 10.1172/JCI114268.
The effect of PG on patients with fulminant and subfulminant viral hepatitis (FHF) was studied. 17 patients presented with FHF secondary to hepatitis A (n = 3), hepatitis B (n = 6), and non-A, non-B (NANB) hepatitis (n = 8). 14 of the 17 patients had stage III or IV hepatic encephalopathy (HE). At presentation the mean aspartate transaminase (AST) was 1,844 +/- 1,246 U/liter, bilirubin 232 +/- 135 mumol/liter, prothrombin time (PT) 34 +/- 18, partial thromboplastin time (PTT) 73 +/- 26 s, and coagulation Factors V and VII 8 +/- 4 and 9 +/- 5%, respectively. Intravenous PGE1 was initiated 24-48 h later after a rise in AST (2,195 +/- 1,810), bilirubin (341 +/- 148), PT (36 +/- 15), and PTT (75 +/- 18). 12 of 17 responded rapidly with a decrease in AST from 1,540 +/- 833 to 188 +/- 324 U/liter. Improvement in hepatic synthetic function was indicated by a decrease in PT from 27 +/- 7 to 12 +/- 1 s and PTT from 61 +/- 10 to 31 +/- 2 s, and an increase in Factor V from 9 +/- 4 to 69 +/- 18% and Factor VII from 11 +/- 5 to 71 +/- 20%. Five responders with NANB hepatitis relapsed upon discontinuation of therapy, with recurrence of HE and increases in AST and PT, and improvement was observed upon retreatment. After 4 wk of intravenous therapy oral PGE2 was substituted. Two patients with NANB hepatitis recovered completely and remained in remission 6 and 12 mo after cessation of therapy. Two additional patients continued in remission after 2 and 6 mo of PGE2. No relapses were seen in the patients with hepatitis A virus and hepatitis B virus infection. Liver biopsies in all 12 surviving patients returned to normal. In the five nonresponders an improvement in hepatic function was indicated by a fall in AST (3,767 +/- 2,611 to 2,142 +/- 2,040 U/liter), PT (52 +/- 25 to 33 +/- 18 s), and PTT (103 +/- 29 to 77 +/- 44 s), but all deteriorated and died of cerebral edema (n = 3) or underwent liver transplantation (n = 2). These results suggest efficacy of PGE for FHF, and further investigation is warranted.
研究了前列腺素(PG)对暴发性和亚暴发性病毒性肝炎(FHF)患者的影响。17例患者表现为FHF,继发于甲型肝炎(n = 3)、乙型肝炎(n = 6)和非甲非乙型(NANB)肝炎(n = 8)。17例患者中有14例处于Ⅲ期或Ⅳ期肝性脑病(HE)。就诊时,平均天冬氨酸转氨酶(AST)为1844±1246 U/升,胆红素为232±135 μmol/升,凝血酶原时间(PT)为34±18,部分凝血活酶时间(PTT)为73±26秒,凝血因子V和VII分别为8±4%和9±5%。在AST(2195±1810)、胆红素(341±148)、PT(36±15)和PTT(75±18)升高后24 - 48小时开始静脉注射前列腺素E1(PGE1)。17例患者中有12例迅速出现反应,AST从1540±833 U/升降至188±324 U/升。PT从27±7秒降至12±1秒,PTT从61±10秒降至31±2秒,凝血因子V从9±4%升至69±18%,凝血因子VII从11±5%升至71±20%,表明肝脏合成功能有所改善。5例NANB肝炎反应者在治疗中断后复发,出现HE复发以及AST和PT升高,再次治疗后观察到病情改善。静脉治疗4周后改用口服前列腺素E2(PGE2)。2例NANB肝炎患者完全康复,在治疗停止后6个月和12个月仍处于缓解期。另外2例患者在接受PGE2治疗2个月和6个月后继续缓解。甲型肝炎病毒和乙型肝炎病毒感染患者未见复发。所有12例存活患者的肝活检恢复正常。5例无反应者肝功能有所改善,表现为AST(从3767±2611 U/升降至2142±2040 U/升)、PT(从52±25秒降至33±18秒)和PTT(从103±29秒降至77±44秒)下降,但最终均病情恶化,3例死于脑水肿,2例接受了肝移植。这些结果表明PGE对FHF有效,值得进一步研究。